Share your videos with the world

Sign Up | Log In | Help  

   
 
Related Tags: cvs  health  pharmacy  medicine  lung  force  cancer  funding  healthcare  donation  multivu  7817251  mother  parenthood  baby  pregnancy  health  medical  science  technology  voice  multivu  7859951  health  medical  technology  research  blood  donation  blood  bank  testing  cure  multivu  7855451  health  healthcare  webmd  baby  child  medicine  treatment  operation  doctor  multivu  7579754  health  healthcare  heart  therapy  surgery  hospital  treatment  transcatheter  medicine  multivu  7049452  health  supplement  joint  pain  gopo  natural  plant  based  medicine  treatment  mobility  multivu  7918251  livanova  medical  technology  therapy  health  treatment  drug  vns  epilepsy  multivu  7966451  webmd  cancer  health  robin  roberts  dogs  detection  treatment  smell  medical  multivu  7579755  research  blood  cancer  cancer  cure  treatment  health  medical  grants  fund  multivu  7554855  yas  island  travel  vacation  entertainment  sea  world  animals  marine  life  theme  park  research  multivu  8002251  yas  island  travel  vacation  entertainment  sea  world  animals  marine  life  theme  park  research  multivu  8002251  medicine  cabinet  winter  makeover  tips  health  cold  clean  dispose  multivu  7974981 
Search // medicine
Results 121-132 of 137 for ' medicine ' (0 seconds)
Teaming up with the American Diabetes Association® and the multi-talented performer and caretaker Joey Fatone @RealJoeyFatone, Colgate Total® is using the power of laughter to help raise awareness of the potential link between oral health and diabetes with the new “30 Days of Laughter” campaign (#30DaysofLOL), beginning today. The 30 days from November 12 to December 11, 2015 will be filled with laugh-out-loud videos, funny social media posts, engaging apps and more to make the diabetes community laugh, all while building awareness of the importance of maintaining the health of the teeth and gums behinds those smiles. According to the Centers for Disease Control and Prevention, people with diabetes are two times more likely to develop gum disease1. Colgate Total® toothpaste can help prevent and even reverse gingivitis, the most common form of gum disease. It is the only FDA-approved and American Dental Association-accepted2 toothpaste to help prevent gingivitis. With regular twice daily brushing, you can help improve your gum health in as little as four weeks3 with Colgate Total®. Understanding how challenging managing diabetes can sometimes be, the funny and talented performer Joey Fatone is leading the “30 Days of Laughter” campaign to remind people that sometimes laughter can feel like the best medicine. “When my father was diagnosed with Type 2 diabetes, our family was shocked. But we’re a big, loving group and we all help him together every day. I know that humor in the face of challenges is vital and I’m excited to share that with other families touched by diabetes.” To view the multimedia release go to: http://www.multivu.com/players/English/7654951-colgate-30-days-of-laughter/
Categories // Miscellaneous 
Added: 3059 days ago by MultiVuVideos
Runtime: 0m38s | Views: 924 | Comments: 1
Not yet rated
 

 

 

The most detailed analysis yet of the role germline mutations in genes associated with cancer predisposition play in the development of childhood cancer suggests that comprehensive genomic screening may be warranted on all pediatric cancer patients, not just those with a family history of cancer. The study from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project appears in the November 19 edition of the New England Journal of Medicine. Ultimately, researchers anticipate that systematic monitoring of patients and family members who have germline mutations in cancer predisposition genes will allow the detection of cancers at their earliest and most curable stage, thereby improving the outcomes for these children and family members. To view the multimedia release go to: http://www.multivu.com/players/English/7692851-st-jude-hospital-genome-project/
Categories // Miscellaneous 
Added: 3052 days ago by MultiVuVideos
Runtime: 2m18s | Views: 551 | Comments: 0
Not yet rated
 

 

 

Adolescents and young adults with a severe inherited immunodeficiency disorder improved following treatment with novel gene therapy developed at St. Jude Children’s Research Hospital and at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The results of this study appear today in the journal Science Translational Medicine. The study involved five males with X-linked severe combined immunodeficiency disease (SCID-X1), also known as “Bubble Boy” disease, who were all treated at NIAID. This inherited disorder involves a mutation in the IL2RG gene that affects males and occurs in 1 of every 50,000 to 100,000 live births, leaving them with little to no immune protection. To view the multimedia release go to: http://www.multivu.com/players/English/7808651-st-jude-gene-therapy-results/
Categories // Miscellaneous 
Added: 2898 days ago by MultiVuVideos
Runtime: 1m41s | Views: 561 | Comments: 0
Not yet rated
 

 

 

Combining their expertise in clinical trials support and cellular therapies, BloodCenter of Wisconsin (BCW) and the San Diego Blood Bank (SDBB) have created a strategic partnership to accelerate advancements in research and patient care. Together, BloodCenter of Wisconsin and San Diego Blood Bank will offer Celluvative™ – a portfolio of products and clinical trial services that will include esoteric laboratory testing, blood products for research and manufacturing applications, cell processing, and access to a broad database of diverse donors who have expressed interest in clinical trials. “Through the strength of our partnership, we are able to offer end-to-end services to academic organizations, research institutions and other industry partners who are working to develop novel cellular therapy approaches,” said Matthew Anderson, M.D., Ph.D., medical director, BloodCenter of Wisconsin Diagnostic Laboratories. “Among other offerings, our Celluvative portfolio enables access to an extremely diverse donor database – an invaluable resource to enable advances in the area of regenerative medicine and drug discovery.” To view the multimedia release go to: http://www.multivu.com/players/English/7855451-bloodcenter-sdbb-celluvative/
Categories // Miscellaneous 
Added: 2849 days ago by MultiVuVideos
Runtime: 2m46s | Views: 684 | Comments: 1
Not yet rated
 

 

 

The foetus moves its mouth in an exaggerated manner when it hears a human voice. This occurs from the 16th week of pregnancy (with a foetus of 11cm) and only when the voice reaches it through an intravaginal device developed for this purpose. This is one of the conclusions of the study presented by Dr. Álex García-Faura, the Scientific Director of the Institut Marquès, at the 25th European Congress of Perinatal Medicine held in Maastricht (Netherlands). The study finds that babies hear practically no external noise and only react when sound reaches them through the vagina, which confirms that they hardly hear voices through the mother’s abdomen. Their reactions were studied using Babypod®, a small device that is inserted into the vagina like a tampon and is connected to a mobile phone, enabling the voice of the mother or anyone else to reach the foetus. To view the multimedia release go to: http://www.multivu.com/players/uk/7859951-institut-marques-babies-react-mother-voice/
Categories // Miscellaneous 
Added: 2842 days ago by MultiVuVideos
Runtime: 1m55s | Views: 679 | Comments: 0
Not yet rated
 

 

 

LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world. One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom. “Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.” To view the multimedia release go to: http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
Categories // Miscellaneous 
Added: 2695 days ago by MultiVuVideos
Runtime: 5m11s | Views: 736 | Comments: 0
Not yet rated
 

 

 

Today, WebMD released The Cutting Edge of Cancer a five-part investigative video series developed in partnership with Robin Roberts and her independent production company, Rock’n Robin Productions. Through compelling patient stories and insights from medical experts, The Cutting Edge of Cancer, supported by Cancer Treatment Centers of America®, highlights some of the most promising areas of medical innovation in cancer care, including early detection, immunotherapy, genomic research, and integrative medicine. To view the multimedia release go to: http://www.multivu.com/players/English/7579755-webmd-robin-roberts-cutting-edge-of-cancer/
Categories // Miscellaneous 
Added: 2689 days ago by MultiVuVideos
Runtime: 0m30s | Views: 606 | Comments: 0
Not yet rated
 

 

 

The Leukemia & Lymphoma Society (LLS) today announced it has committed $40.3 million in new research investments to advance the most promising blood cancer science at leading academic and medical centers around the world, including Dana-Farber Cancer Institute in Boston; Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center in New York; MD Anderson Cancer Center in Houston; Fondazione Centro San Raffaele in Milan; and South Australian Health & Medical Research Institute in Adelaide. This $40.3 million investment, comprised of 75 new research grants in LLS’s portfolio of 300 projects, will fund a diverse array of research to find better treatments and cures for patients with leukemia, lymphoma, myeloma and other blood cancers. To view the multimedia release go to: http://www.multivu.com/players/English/7554855-lls-invests-millions-new-research-treatment-cures/
Categories // Miscellaneous 
Added: 2689 days ago by MultiVuVideos
Runtime: 0m47s | Views: 640 | Comments: 0
Not yet rated
 

 

 

Miral and SeaWorld Entertainment, Inc. (NYSE:SEAS) (“SeaWorld”) today announced their partnership to develop SeaWorld Abu Dhabi, a first-of-its-kind marine life themed park on Yas Island. This next generation SeaWorld Abu Dhabi will also include the United Arab Emirates’ (“UAE”) first dedicated marine life research, rescue, rehabilitation and return center with world-class facilities and resources for the care and conservation of local marine life. SeaWorld Abu Dhabi will be the first new SeaWorld without orcas, and will integrate up-close animal experiences, mega attractions and a world class aquarium, bringing the latest technology in visitor engagement. The partnership brings together Miral’s expertise in developing Yas Island’s portfolio of destinations with SeaWorld’s 50-plus years of theme park, veterinary medicine, marine science and zoological practice and experience. To view the multimedia release go to: http://www.multivu.com/players/uk/8002251-miral-announces-seaworld-yas-island/
Categories // Miscellaneous 
Added: 2661 days ago by MultiVuVideos
Runtime: 1m39s | Views: 690 | Comments: 0
Not yet rated
 

 

 

Miral and SeaWorld Entertainment, Inc. (NYSE:SEAS) (“SeaWorld”) today announced their partnership to develop SeaWorld Abu Dhabi, a first-of-its-kind marine life themed park on Yas Island. This next generation SeaWorld Abu Dhabi will also include the United Arab Emirates’ (“UAE”) first dedicated marine life research, rescue, rehabilitation and return center with world-class facilities and resources for the care and conservation of local marine life. SeaWorld Abu Dhabi will be the first new SeaWorld without orcas, and will integrate up-close animal experiences, mega attractions and a world class aquarium, bringing the latest technology in visitor engagement. The partnership brings together Miral’s expertise in developing Yas Island’s portfolio of destinations with SeaWorld’s 50-plus years of theme park, veterinary medicine, marine science and zoological practice and experience. To view the multimedia release go to: http://www.multivu.com/players/uk/8002251-miral-announces-seaworld-yas-island/
Categories // Miscellaneous 
Added: 2661 days ago by MultiVuVideos
Runtime: 1m8s | Views: 665 | Comments: 0
Not yet rated
 

 

 

Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today. Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated. To view the multimedia release go to: https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
Categories // Miscellaneous 
Added: 2388 days ago by MultiVuVideos
Runtime: 1m0s | Views: 619 | Comments: 3
Not yet rated
 

 

 

Lustgarten Foundation funded researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins have designed a multi-analyte blood test that can detect the presence of pancreatic cancer as part of a panel of eight common cancers (pancreas, ovary, liver, stomach, esophagus, colorectum, lung and breast) as reported in the online edition of Science today. The test utilizes combined assays for genetic alterations and protein biomarkers and has the capacity not only to identify the presence of relatively early cancer, but also to localize the organ of origin of these cancers. “The potential this has for pancreatic cancer is unprecedented,” says Anne Marie Lennon, M.D., Ph.D., Associate Professor of Medicine, Director, Pancreatic Cyst Center of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center. “We know that in 80-85 percent of pancreatic cancer cases, it’s detected too late, leaving the patient with few options. Developing a blood screening test for pancreatic cancer has been an urgent goal, because catching the disease early will be the way we get to long-term survival.” To view the multimedia release go to: https://www.multivu.com/players/English/8213751-lustgarten-foundation-pancreatic-cancer-blood-test/
Categories // Miscellaneous 
Added: 2260 days ago by MultiVuVideos
Runtime: 2m0s | Views: 627 | Comments: 2
Not yet rated
 

 

 

Page 11 of 12  |  Go to page     |  ««FIRST «Previous  Next» LAST»»



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2024 ClipMoon.com. All rights reserved.